Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

DCIS: early-phase trial registry

6 of 10 indexed DCIS trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 6 currently recruiting · #1,724 of 28,707 conditions by registered trial count

DCIS: 10 US clinical trials tracked, 6 recruiting.

DCIS is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Rita Sanghvi, Mehta, running 1 of these trials.

Enrollment posture brief

Registry condition dcis

OPEN 6 | RECR 60% | LATE 1 | EARLY 6 | RANK #1724 | SPON 1

Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)

Acute Leukemia of Ambiguous 80%DCIS (this)60%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near DCIS

DCIS lists 6 open slots (60% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for DCIS on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. DCIS is recruiting above its size-band peers.

    6 of 10 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of DCIS trials is spread across many organizations.

    Rita Sanghvi, Mehta accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Typical DCIS enrolment sits around 100 participants.

    Median target enrolment is 100 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. DCIS research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 3,000 participants

The PREDICT Registry:

PreludeDx

NCT03448926

RECRUITING Phase 3 500 participants

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

Uppsala University

NCT04722692

RECRUITING Phase 2 280 participants

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT04084730

RECRUITING Phase 2 90 participants

Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)

UNC Lineberger Comprehensive Cancer Center

NCT06902311

RECRUITING Phase 2 30 participants

Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer

University of Wisconsin, Madison

NCT03936478

RECRUITING NA 24 participants

Perioperative Mindfulness Proposal

Hoag Memorial Hospital Presbyterian

NCT04049214

ACTIVE NOT RECRUITING NA 997 participants

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

Alliance Foundation Trials

NCT02926911

ACTIVE NOT RECRUITING Phase 1 100 participants

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Integro Theranostics

NCT05900986

COMPLETED Phase 1 58 participants

DC Vaccine for Patients With Ductal Carcinoma In Situ

Abramson Cancer Center at Penn Medicine

NCT02061332

COMPLETED Phase 2 42 participants

Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

Rita Sanghvi, Mehta

NCT00256217

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on DCIS records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

HER-2 Pulsed Dendritic cell Vaccine Biological
1 trials
LS301-IT 0.075 mg/kg Drug
1 trials
LS301-IT 0.05 mg/kg Drug
1 trials
LS301-IT 0.025 mg/kg Drug
1 trials
Active Monitoring Other
1 trials
Surgery Other
1 trials
MRIdian Radiation Treatment Unit Radiation
1 trials
Meditation Other
1 trials

US sites by state

Facility locations filed on DCIS trials. A trial with sites in several states counts in each.

Florida 4 trials
California 4 trials
Texas 3 trials
New York 3 trials
Arizona 3 trials
Pennsylvania 2 trials
Ohio 2 trials
North Carolina 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this DCIS page

10 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This DCIS condition card totals 10 registered trials; most-linked intervention HER-2 Pulsed Dendritic cell Vaccine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.